GlassScriptPhysician profile
Patra Fazel
NPI 1295972867
$2,165.59
in general payments reported to CMS, 2019-2025
15 companies · $502 in 2025
The $502 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2022: $303 · 2023: $683 · 2024: $247 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $371.48 | 2023-2025 | Infuse, Miebo, Multi-Focal |
| Lkc Technologies, INC. | $272.03 | 2023-2025 | |
| Abbvie INC. | $222.52 | 2022-2023 | |
| Lumenis Be INC | $168.50 | 2023 | Optilight |
| Aerie Pharmaceuticals, INC. | $127.47 | 2019 | |
| Genentech USA, INC. | $122.16 | 2019 | |
| Genzyme Corporation | $121.95 | 2019 | |
| Alcon Vision LLC | $121.82 | 2025 | Tryptyr |
| Sun Pharmaceutical Industries INC. | $119.27 | 2023 | Cequa |
| Oyster Point Pharma, INC. | $114.58 | 2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $108.83 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $88.05 | 2022 | |
| Dompe US, INC. | $78.46 | 2025 | Oxervate |
| Glaukos Corporation | $69.83 | 2025 | Idosetr |
| Optos, INC. | $58.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patra Fazel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.